Allergan, Inc.

Allergan Announces Agreement to Acquire Aczone Gel 5%

Published in Lab Law Weekly, June 27th, 2008

Allergan, Inc. (NYSE:AGN) announced that its wholly-owned subsidiary, Allergan Sales, LLC, has entered into an agreement with QLT USA, Inc., a wholly-owned subsidiary of QLT Inc. (NASDAQ:QLTI) (TSX:QLT), to acquire QLT's Aczone(R) (dapsone) Gel 5% product, a topical treatment for acne vulgaris.

Aczone(R) Gel 5% is indicated in the United States and Canada for the treatment of acne vulgaris in patients 12 years and older. In two randomized, double-blind, vehicle controlled clinical studies involving approximately 3,000 patients, Aczone(R) Gel 5% achieved a statistically significant reduction in the number of acne lesions and a better success rate relative to vehicle use...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Law Weekly

Source: Lab Law Weekly (2008-06-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry